Vaccines News and Research RSS Feed - Vaccines News and Research

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR). [More]
Researchers awarded grant from British Council to reduce burden of infectious disease in Malaysia

Researchers awarded grant from British Council to reduce burden of infectious disease in Malaysia

A group of collaborators led by the University of Southampton have been awarded a British Council Newton Fund Institutional Links Grant to support ground-breaking research towards reducing the burden of infectious disease in Malaysia. [More]
Parents' views on safety and benefits of vaccines have shifted, finds new poll

Parents' views on safety and benefits of vaccines have shifted, finds new poll

Over the same time period that multiple outbreaks of measles and whooping cough made headlines around the country, parents' views on vaccines became more favorable, according to a new nationally-representative poll. [More]
More than 34 million children's lives saved since 2000 through low-cost investments in health programs

More than 34 million children's lives saved since 2000 through low-cost investments in health programs

More than 34 million children's lives have been saved since 2000 because of investments in child health programs at a cost of as little as $4,205 per child, according to a new analysis in The Lancet. [More]
Creating more effective vaccines against flu virus

Creating more effective vaccines against flu virus

Flu vaccines can be something of a shot in the dark. Not only must they be given yearly, there's no guarantee the strains against which they protect will be the ones circulating once the season arrives. New research by Rockefeller University scientists and their colleagues suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus. [More]
Research finding could lead to first effective therapies, vaccines against dengue virus

Research finding could lead to first effective therapies, vaccines against dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus. [More]
Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Is it possible to predict the evolution of the influenza virus? Or how rapidly bacteria evolve resistance to antibiotics? Or even how cancer cells spread inside a human being? These are some of the main topics of discussion that bring together renowned scientists from all over the world at the scientific conference "Forecasting evolution?" held at the Calouste Gulbenkian Foundation (FCG; Portugal) from 8th to 11th July. [More]
Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li, a professor and director of the Institute for Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 million federal grant to develop novel anti-inflammatory therapeutics against middle-ear infections. [More]
Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. [More]
Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018. [More]
SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine. [More]
TSRI-led study identifies new immune molecules that protect against Marburg virus

TSRI-led study identifies new immune molecules that protect against Marburg virus

A new study led by scientists at The Scripps Research Institute identifies new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The research provides ingredients needed to develop treatments for future Marburg outbreaks. [More]
Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia. [More]
Texas Biomed, Take Off Pounds Sensibly establish new TOPS Nutrition and Obesity Research Center

Texas Biomed, Take Off Pounds Sensibly establish new TOPS Nutrition and Obesity Research Center

Texas Biomedical Research Institute and Wisconsin-based non-profit Take Off Pounds Sensibly are establishing the new TOPS® Nutrition and Obesity Research Center with the goal of conducting research into the causes, health risks and treatment of human obesity. Studies at the Center will focus on the role of genetic predisposition to metabolic changes, nutritional preferences, appetite regulation, food intake and choice and incidence of obesity-related illnesses. [More]
Caya contoured diaphragm to expand U.S. women's options for nonhormonal barrier contraception

Caya contoured diaphragm to expand U.S. women's options for nonhormonal barrier contraception

With the launch of the Caya contoured diaphragm this June, women in the United States will have access to a method of contraception that is nonhormonal, has few side effects, and can be used for up to two years. Last fall, the United States Food and Drug Administration cleared the single-size Caya contoured diaphragm for marketing in the US, and now the diaphragm is available by prescription from healthcare providers. [More]
Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Study may help find strategies to control mosquito populations

Study may help find strategies to control mosquito populations

Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes -- one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time -- creating a strong signature of local adaptation to environment and humans. [More]
Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration. [More]
Study: Cellular respiration separates effects of bactericidal and bacteriostatic antibiotics

Study: Cellular respiration separates effects of bactericidal and bacteriostatic antibiotics

Antibiotics are the mainstay in the treatment of bacterial infections, and together with vaccines, have enabled the near eradication of infectious diseases like tuberculosis, at least in developed countries. [More]
Advertisement
Advertisement